

FluCov-Bulletin – April 2023

FluCov project: combining data from around the world to better understand the impact of COVID-19 on influenza activity

Commentary

Contents

It is now more than three years since a cluster of atypical pneumonia cases in Wuhan, China, was reported to the World Health Organization (WHO) (January 1, 2020) that was later linked to the new **SARS-CoV-2** virus. The FluCov Bulletin provides an overview of the number of positive cases of influenza and **SARS-CoV-2** and the percentage of specimens that tested positive from January 2019 onwards in 22 countries across most regions of the world (see page 3).

Results

Globally, influenza activity has decreased (see Figure 1). The following country patterns were observed for influenza in April 2023:

- Influenza detections in China decreased over the month of April, after a large peak, observed in March, driven by a mix of influenza A(H1N1)pdm09 and A(H3N2).
- In all countries that reported a wave of influenza B (France, Germany, Italy, Poland, Spain and Brazil), a decrease in influenza detections was observed. Detections also decreased in the Netherlands, where a mix of influenza A and B was present.
- A small increase in **influenza** detections was observed in two of the Southern Hemisphere countries, covered by the Bulletin (**Australia** and **South Africa**). In **South Africa**, the percentage of positive tests is increasing in a similar manner to previous seasons.
- In South Korea, a small increase in influenza A(H3N2) detections was observed. In other Asian countries, influenza activity was low (India, Philippines, Thailand, Vietnam) or decreasing (China, Japan).
- Low influenza activity was also observed in the United States (a mix inf A and B) as well as in Canada, Mexico, United Kingdom and Egypt (all influenza B/Victoria or B lineage not determined).

Globally, **SARS-CoV-2** detections have been generally low after the peak in China, late 2022 (see Figure 1). The following country patterns were observed for **SARS-CoV-2** in April 2023:

- Relatively low numbers SARS-CoV-2 detections, with some small increases or decreases, were reported in most countries in the Bulletin: Australia, Brazil, Canada, China, Egypt, France, Germany, India, Israel, Italy, Mexico, Netherlands, Philippines, Poland, South Africa, Spain, Thailand, United Kingdom, United States and Vietnam
- A small increase in SARS-CoV-2 detections was observed in South Korea and Japan.

Implications

In all countries that reported a wave of influenza B in February – March, a decrease in detections was observed during April 2023. With the end of this (smaller) influenza B epidemic, the Northern Hemisphere influenza season appears to have ended, following an early season onset and initial peak in December 2022.

It is of note that **South Africa** (A(H1N1)pdm09) and **Australia** (a mix of influenza A and B, undetermined) both observed a small increase in **influenza** detections. This could possibly signal an early start of the 2023 **influenza** season in these two Southern Hemisphere countries. Another Southern Hemisphere country that saw an increase in **influenza** detections (A(H1N1)pdm09) if subtyped) in April was **Chile** [1].

The 2022 season was the first real **influenza** season for the Southern Hemisphere since the onset of the **SARS-CoV-2** pandemic. It started with an **influenza** A epidemic in **Australia**, **Brazil** and **South Africa**, followed by **influenza** B in **South Africa** [2]. Additionally, **Chile** reported an **influenza** A(H3N2) epidemic with an unusually early onset and atypical course [3]. The 2023 season will indicate whether **influenza** activity in the Southern Hemisphere has returned to a pre-**SARS-CoV-2** pattern.

SARS-CoV-2 activity was relatively low in most countries in April. Globally, **SARS-CoV-2** detections have been decreasing since the peak in **China** in December 2022. There are, however, regional differences and small increases in **SARS-CoV-2** detections were seen in South-East Asia, the Eastern Mediterranean and Western Pacific region, according to the WHO [4].

Importantly, WHO has announced that **SARS-CoV-2** is 'is now an established and ongoing health issue which no longer constitutes a public health emergency of international concern (PHEIC)' [5]. Despite this development, it is important to note that many countries are still reporting high numbers of **SARS-CoV-2** detections (e.g. there were 82,394 in **Australia**, 350,756 in **Korea**, 214,856 in **France** and 568,838 in the **United States** during the month of April 2023) and the surveillance of **SARS-CoV-2** will remain very important in the coming 12 months.



Figure 1: SARS-CoV-2 and influenza detections in the 22 countries covered by the Bulletin (period: from week 1/2019 to week 17/2023)

Disclaimer: Comparisons <u>between countries and seasons</u> of influenza and SARS-CoV-2 detections should be made with care, as national surveillance systems may differ (e.g. surveillance structures and testing intensity) and change over time.

Monthly plots by country

The plots per country show weekly data for influenza and of SARS-CoV-2 infections from 1 January, 2019 up to 30 April, 2023. This FluCov-Bulletin includes the countries Canada, United States, Mexico, Brazil, United Kingdom, France, Germany, Italy, Netherlands, Spain, Poland, South Africa, Egypt, China, Japan, South Korea, India, Philippines, Thailand, Vietnam, Israel and Australia.

Per country, the first plot displays the number of positive influenza (in blue) and SARS-CoV-2 (in red) detections. An overview of the absolute number of influenza and of SARS-CoV-2 detections per country can be found on pages 26-28 of this FluCov-Bulletin (click here). The bar displays the Stringency Index (SI; a country-specific composite metric of the mitigation measures that are in place) over time. The second plot shows the influenza detections by subtypes/lineages reported to FluNet. The third plot displays the percentage of specimens testing positive for influenza during the current season (in red), the last season, and the average of the two pre COVID-19 seasons (2017-18 and 2018-19)

The FluCov Dashboard is live!

All Figures and Tables in the FluCov-Bulletin can now be accessed (real-time) at: https://www.nivel.nl/en/dossier-epidemiology-respiratory-viruses/flucov-dashboard

Countries (click to view plot)

North America Canada United States	Northern Africa Egypt
	Southern Africa
Central America Caribbean Mexico	South Africa
	Eastern Asia
Tropical South America	China
Brazil	Japan
	South Korea
Northern Europe	
United Kingdom	Southern Asia India
Eastern Europe	
Poland	South East Asia Philippines
South West Europe	Thailand
France	Vietnam
Germany	
Italy	Western Asia
Netherlands	Israel
Spain	
	Oceania
	Australia



North America

Percentage of specimens testing positive for influenza in different seasons



Nivel

United States



Percentage of specimens testing positive for influenza in different seasons





Central America Caribbean

Percentage of specimens testing positive for influenza in different seasons





Tropical South America

Percentage of specimens testing positive for influenza in different seasons





Northern Europe

Percentage of specimens testing positive for influenza in different seasons: data not available

Eastern Europe



Percentage of specimens testing positive for influenza in different seasons



Season

- Pre-COVID-19 (2017-2019 avg.)
- 2022
- _____ 2023

Nivel



South West Europe







- Pre-COVID-19 (2017-2019 avg.)
- 2022
- 2023

Germany



Percentage of specimens testing positive for influenza in different seasons



Season

- Pre-COVID-19 (2017-2019 avg.)
- 2022
- 2023





Percentage of specimens testing positive for influenza in different seasons



Netherlands



Percentage of specimens testing positive for influenza in different seasons: data not available

Spain



Percentage of specimens testing positive for influenza in different seasons



Northern Africa



Percentage of specimens testing positive for influenza in different seasons





Southern Africa





Season

- Pre-COVID-19 (2017-2019 avg.)
- 2022
- 2023

Eastern Asia



Note: Due to a high number of retrospectively added SARS-CoV-2 detections, the peak in China in late 2022 increased significantly, compared to previous Bulletins.



Percentage of specimens testing positive for influenza in different seasons





Percentage of specimens testing positive for influenza in different seasons: data not available

South Korea



Percentage of specimens testing positive for influenza in different seasons





Percentage of specimens testing positive for influenza in different seasons





Philippines



Percentage of specimens testing positive for influenza in different seasons: data not available

Thailand



Percentage of specimens testing positive for influenza in different seasons



- Pre-COVID-19 (2017-2019 avg.)
- 2022
- 2023

Vietnam



Percentage of specimens testing positive for influenza in different seasons





- Pre-COVID-19 (2017-2019 avg.)
- 2022
- 2023

Western Asia





Percentage of specimens testing positive for influenza in different seasons



Oceania





Percentage of specimens testing positive for influenza in different seasons



Absolute numbers per country

Country	Year	Cases ^{a,b} of	+/- since	Cases ^a of	+/- since	Week of last
		SARS-CoV-2	last month ^c	influenza	last month ^c	influenza update
Australia	2019			12,404		
Australia	2020	28,381		784		
Australia	2021	338,226		8		
Australia	2022	10,418,952		12,312		
Australia	2023	425,092	82,394	846	345	2023-16
Brazil	2019			3,320		
Brazil	2020	7,563,551		1,361		
Brazil	2021	14,700,856		1,240		
Brazil	2022	14,038,581		3,648		
Brazil	2023	1,147,003	190,755	2,411	550	2023-16
Canada	2019			43,196		
Canada	2020	565,508		44,956		
Canada	2021	1,536,966		337		
Canada	2022	2,390,159		71,314		
Canada	2023	167,342	33,000	8,441	2,066	2023-16
China	2019			122,757		
China	2020	96,673		31,164		
China	2021	35,398		25,812		
China	2022	86,958,455		56,455		
China	2023	12,156,715	8,263	110,241	28,411	2023-16
Egypt	2019			1,998		
Egypt	2020	136,644		659		
Egypt	2021	248,084		233		
Egypt	2022	130,786		2,709		
Egypt	2023	456	88	357	42	2023-15
France	2019			25,405		
France	2020	2,564,972		16,589		
France	2021	6,917,610		3,071		
France	2022	28,717,231		40,126		
France	2023	725,548	214,856	18,169	808	2023-16
Germany	2019			1,215		
Germany	2020	1,734,450		958		
Germany	2021	5,430,620		29		
Germany	2022	30,220,403		1,923		
Germany	2023	1,018,194	51,257	507	55	2023-16
India	2019			10,426		
India	2020	10,266,679		652		
India	2021	24,572,130		4,789		
India	2022	9,840,329		1,421		
India	2023	267,005	229,603	1,143	178	2023-16
Israel	2019			1,796		
Israel	2020	419,661		1,424		
Israel	2021	962,277		456		
Israel	2022	3,381,636		774		
Israel	2023	58,206	7,723	801	0	2023-13

SARS-CoV-2 last month ^c influenza last month ^c influenza	a unadata -
	aupdate
Italy 2019 2,787	
Italy 2020 2,083,689 7,485	
Italy 2021 3,897,739 31	
Italy 2022 19,187,010 5,817	
Italy 2023 619,949 93,076 2,415 183	2023-16
Japan 2019 10,343	
Japan 2020 230,304 2,915	
Japan 2021 1,503,484 9	
Japan 2022 27,478,747 239	
Japan 2023 4,501,482 272,573 1,836 30	2023-15
Mexico 2019 6,963	
Mexico 2020 1,496,068 4,799	
Mexico 2021 2,538,755 960	
Mexico 2022 3,236,612 10,314	
Mexico 2023 316,013 39,076 1,374 93	2023-16
Netherlands 2019 5,166	
Netherlands 2020 785,874 3,235	
Netherlands 2021 2,329,020 471	
Netherlands 2022 5,454,287 11,082	
Netherlands 2023 41,191 914 9,088 195	2023-17
Philippines 2019 612	
Philippines 2020 472,523 52	
Philippines 2021 2,371,346 105	
Philippines 2022 1,218,790 260	
Philippines 2023 29,195 10,897 80 8	2023-16
Poland 2019 1,786	
Poland 2020 1,297,400 1,282	
Poland 2021 2,811,801 2	
Poland 2022 2,259,187 1,604	
Poland 2023 145,493 17,705 1,833 77	2023-16
South Africa 2019 1,164	
South Africa 2020 1,039,161 157	
South Africa 2021 2,407,371 413	
South Africa 2022 602,048 1,171	
South Africa 2023 23,953 0 79 49	2023-16
South Korea 2019 1,702	
South Korea 2020 60,722 505	
South Korea 2021 574,528 0	
South Korea 2022 28,481,550 295	
South Korea 2023 2,054,086 350,756 450 99	2023-16
Spain 2019 16,580	
Spain 2020 1,955,216 8,827	
Spain 2021 4,550,685 2,206	
Spain 2022 7,178,357 17,236	
Spain 2023 140,794 34,472 7,168 485	2023-16
Thailand 2019 1,568	
Thailand 2020 6,919 297	
Thailand 2021 2,216,551 23	
Thailand 2022 2,500,484 575	
Thailand 2023 8,382 3,669 307 41	2023-16

Country	Year	Cases ^{a,b} of	+/- since	Cases ^a of	+/- since	Week of last
United Kingdom	2010	JANJ-CUV-2				innuenza upuate
United Kingdom	2019			42,447		
United Kingdom	2020	2,563,565		14,369		
United Kingdom	2021	10,878,109		2,755		
United Kingdom	2022	10,752,285		26,904		
United Kingdom	2023	387,747	57,611	5,271	282	2023-16
United States	2019			268,524		
United States	2020	19,577,585		229,766		
United States	2021	33,956,701		39,507		
United States	2022	45,877,410		470,066		
United States	2023	3,854,708	568,838	36,299	1,734	2023-16
Vietnam	2019			355		
Vietnam	2020	1,456		146		
Vietnam	2021	1,729,801		39		
Vietnam	2022	9,793,974		106		
Vietnam	2023	34,631	32,577	12	4	2023-16

^a Laboratory-confirmed cases.

^b As of the 24th bulletin, the data source, used by Our World In Data, for SARS-CoV-2 cases has been changed

retrospectively. As a result, yearly totals displayed in this table may differ from those in previous bulletins. ^c Influenza cases are reported by FluNet on a weekly basis. To convert these data to months, weekly data are assigned

to the month most days in that week belong to. SARS-CoV-2 cases are reported per day and assigned to each month by date. +/- since last month includes all cases over the last full calendar month.

Methodology

Background

After assessment of alarming levels of spread and severity of SARS-CoV-2 virus, on March 11, 2020, WHO declared COVID-19 a pandemic [6]. The emergence of this new virus has had a major impact on the global circulation of respiratory viruses, including influenza and RSV [7]. The FluCov project aims to understand and communicate the impact of COVID-19 on: i) influenza activity and ii) prevention and control measures (e.g. vaccination) in the coming years.

Scope

The countries included in this FluCov-Bulletin are distributed over the Americas (North, Central and Tropical South), Europe (Northern, South West and Eastern), Africa (Northern and Southern), Asia (Eastern, Southern, South East and Western) and Oceania. These data are compared to the prevention and control measures applied in each country using the Stringency Index from the Oxford COVID-19 Government Response Tracker (OxCGRT) [8].

Data sources

- Influenza: FluNet [9] is a global web-based tool for influenza virological surveillance first launched in 1997. The virological data entered into FluNet, e.g. number of influenza viruses detected by subtype, are critical for tracking the movement of viruses globally and interpreting the epidemiological data. The data are provided remotely by National Influenza Centres (NICs) of the Global Influenza Surveillance and Response System (GISRS) and other national influenza reference laboratories collaborating actively with GISRS or are uploaded from WHO regional databases.
- SARS-CoV-2: Our World in Data systematically collects COVID-19 data which is presented in their online tool [10]. We used this platform to extract data on the number of cases, as well as tests performed per country. As of 8 March 2023, Our World in Data changed their primary data source from the John Hopkins repository on daily confirmed COVID-19 cases to the WHO [11].
- Government response tracker: The Oxford COVID-19 Government Response Tracker (OxCGRT) [8] systematically collects information on several different common policy responses that governments have taken to respond to the pandemic on 20 indicators such as school closures and travel restrictions. It now has data from more than 180 countries. OxCGRT data is downloaded directly from the Our World in Data platform.

Extraction details

Data were extracted on 7 May 2023 and cover the period 1 January 2019 to 6 May 2023 (4 May for SARS-CoV-2). Data from both platforms are regularly updated and **sometimes retrospectively corrected**. This might explain any discrepancies between our reported figures and the data published online, even when using data for the exact same period. In case of any unclarities or perceived irregularities, feel free to contact us at <u>flucov@nivel.nl</u>.

References

- [1] WHO. FluNet. https://www.who.int/tools/flunet [accessed 10 May 2023]
- [2] Nivel. FluCov-Bulletin September 2022. Utrecht; 2022. Report No.: 14.
- [3] Barraza MFO. Influenza Incidence and Vaccine Effectiveness During the Southern Hemisphere Influenza Season—Chile, 2022. MMWR Morbidity and Mortality Weekly Report. 2022;71.
- [4] WHO. Weekly epidemiological update on COVID-19 4 May 2023. <u>Coronavirus Disease (COVID-19) Situation</u> <u>Reports (who.int)</u> [accessed 9 May 2023]
- [5] WHO. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. 5 May 2023. <u>Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the</u> <u>COVID-19 pandemic (who.int)</u> [accessed 9 May 2023]
- [6] WHO. Listing of WHO's response to COVID-19. https://bit.ly/3mIMtRi [accessed 1 July 2022]
- [7] WHO. Influenza Update N° 416. http://bit.ly/3T5SvHV [accessed 7 April 2022]
- [8] Oxford COVID-19 Government Response Tracker, Blavatnik School of Government, University of Oxford. http://bit.ly/41WqmqX [accessed 16 June 2021]
- [9] WHO. FluNet. https://www.who.int/tools/flunet [accessed 8 March 2023]
- [10] Ritchie, H., Ortiz-Ospina, E., Beltekian, D., Mathieu, E., Hasell J., Macdonald B. et al. Coronavirus Pandemic (COVID-19). https://ourworldindata.org/coronavirus [accessed 15 June 2021]
- [11] Mathieu E, Rodés-Guirao L. Our World in Data will rely on data from the WHO to track confirmed COVID-19 cases and deaths. <u>https://ourworldindata.org/covid-jhu-who</u> [accessed 5 April 2023]

Project Team

Nivel, Netherlands: Bronke Boudewijns, Marco Del Riccio, Willemijn van Waarden, Saverio Caini, John Paget

Global Influenza Initiative:

Ben Cowling, School of Public Health, University of Hong Kong, Hong Kong Ann Falsey, Rochester General Hospital, University of Rochester School of Medicine, Rochester, NY Angele Gentile, Ricardo Gutiérrez Children's Hospital, Buenos Aires Jan Kyncl, Department of Infectious Diseases Epidemiology, National Institute of Public Health, Prague Bruno Lina: Virpath Laboratory, University of Lyon, Lyon Raina McIntyre: The Kirby Institute, University of New South Wales, Sydney

Global Influenza Initiative

Sanofi, France: Erica Dueger, Clotilde El Guerche-Séblain, Meral Akçay, Cecile Eymin Websites

Project Website: <u>https://www.nivel.nl/en/flucov</u>

FluCoV Dashboard: https://www.nivel.nl/en/dossier-epidemiology-respiratory-viruses/flucov-dashboard

Funding

The FluCov Project is funded by Sanofi, France.